Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 295

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 295
---
 |                               | –           |     |   |    3,519,702 |     |   |   3,519,702 |

The fair value of other assets and
liabilities, which include cash, amounts receivable, accounts payable and accrued liabilities, and amounts due to related parties, approximate
their carrying values due to the relatively short-term maturity of these instruments.

| b. | Credit Risk |

Financial instruments that potentially
subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure
to credit loss by placing its cash with high credit quality financial institutions. The carrying amount of financial assets represents
the maximum credit exposure.

| c. | Foreign Exchange Rate Risk |

Foreign currency risk is the risk that
the fair value of future cash flows of a financial instrument will fluctuate due to changes in foreign exchange rates. The Company is
exposed to foreign currency risk to the extent that monetary assets and liabilities are denominated in a foreign currency. The Company’s
subsidiary operates in Israel and has certain monetary financial instruments denominated in New Israeli Shekel and CAD. The Company has
not entered into foreign exchange rate contracts to mitigate this risk.

F-55 CLEARMIND MEDICINE INC. Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended July 31, 2025 and 2024 (Expressed in United States Dollars) (Unaudited)

| 10. | Financial Instruments and Risk Management (continued) |

| c. | Foreign Exchange Rate Risk (continued) |

The following table indicates the impact
of foreign currency exchange risk on net working capital as of July 31, 2025. The table below also provides a sensitivity analysis of
a % strengthening of the foreign currency against functional currencies identified which would have increased (decreased) the Company’s
net loss by the amounts shown in the table below.

| Cash and cash equivalents                                           |     | $ | 116,250 |   |
| Other receivables                                                   |     |   |  28,725 |   |
| Accounts payable and accrued liabilities                            |     |   | (65,080 | ) |
| Due to related parties                                              |     |   | (39,820 | ) |
| Total foreign currency financial assets and liabilities             |     | $ |  40,075 |   |
| Impact of a 10% strengthening or weakening of foreign exchange rate |     | $